NZ702801A - Treatment of sanfilippo syndrome type b - Google Patents
Treatment of sanfilippo syndrome type bInfo
- Publication number
- NZ702801A NZ702801A NZ702801A NZ70280111A NZ702801A NZ 702801 A NZ702801 A NZ 702801A NZ 702801 A NZ702801 A NZ 702801A NZ 70280111 A NZ70280111 A NZ 70280111A NZ 702801 A NZ702801 A NZ 702801A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- syndrome type
- sanfilippo syndrome
- formulation
- naglu
- Prior art date
Links
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 title 1
- 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 title 1
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 abstract 2
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000007913 intrathecal administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| NZ605871A NZ605871A (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
| PCT/US2011/041928 WO2011163652A2 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702801A true NZ702801A (en) | 2016-08-26 |
Family
ID=46888842
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702801A NZ702801A (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
| NZ605871A NZ605871A (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ605871A NZ605871A (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110318327A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2585105B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6063380B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20130043166A (cg-RX-API-DMAC10.html) |
| CN (1) | CN103269709A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2011270672B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2805449A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2643015T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2013000324A (cg-RX-API-DMAC10.html) |
| NZ (2) | NZ702801A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011163652A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| CA2803166C (en) | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| JP6045493B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| BR112012033214B1 (pt) | 2010-06-25 | 2020-11-03 | Shire Human Genetic Therapies, Inc. | uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente |
| EP2596123B1 (en) | 2010-07-22 | 2015-11-25 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
| BR112013022557A2 (pt) * | 2011-03-04 | 2017-08-01 | Shire Human Genetic Therapies | ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| WO2013055888A2 (en) * | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| ES2679374T3 (es) * | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| FR3011468B1 (fr) * | 2013-10-04 | 2015-12-04 | Inventiva | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
| EP3160494B1 (en) * | 2014-06-25 | 2019-11-20 | Shire Human Genetic Therapies, Inc. | Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase |
| WO2016025523A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| WO2016025519A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| AU2015323966A1 (en) | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| WO2016065319A1 (en) * | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EP3419651B1 (en) | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| CN112566652A (zh) | 2018-06-25 | 2021-03-26 | Jcr制药股份有限公司 | 含有蛋白的水性液体制剂 |
| CA3192771A1 (en) * | 2020-08-28 | 2022-03-03 | Jcr Pharmaceuticals Co., Ltd. | Mutant of .alpha.-n-acetylglucosaminidase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| DK2020438T3 (en) | 1998-12-07 | 2018-07-23 | Genzyme Corp | Treatment of Pompe disease |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| PT1587923E (pt) | 2003-01-22 | 2011-12-07 | Univ Duke | Construções melhoradas para a expressão de polipéptidos lisossomais |
| WO2005002515A2 (en) * | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| GB0611463D0 (en) * | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| WO2009137721A2 (en) * | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| JP6073783B2 (ja) * | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
-
2011
- 2011-06-25 CN CN2011800407953A patent/CN103269709A/zh active Pending
- 2011-06-25 NZ NZ702801A patent/NZ702801A/en not_active IP Right Cessation
- 2011-06-25 US US13/168,969 patent/US20110318327A1/en not_active Abandoned
- 2011-06-25 ES ES11799039.0T patent/ES2643015T3/es active Active
- 2011-06-25 JP JP2013516847A patent/JP6063380B2/ja not_active Expired - Fee Related
- 2011-06-25 EP EP11799039.0A patent/EP2585105B1/en active Active
- 2011-06-25 AU AU2011270672A patent/AU2011270672B2/en not_active Ceased
- 2011-06-25 KR KR1020137001751A patent/KR20130043166A/ko not_active Ceased
- 2011-06-25 WO PCT/US2011/041928 patent/WO2011163652A2/en not_active Ceased
- 2011-06-25 NZ NZ605871A patent/NZ605871A/en not_active IP Right Cessation
- 2011-06-25 CA CA2805449A patent/CA2805449A1/en not_active Abandoned
- 2011-06-25 MX MX2013000324A patent/MX2013000324A/es unknown
-
2017
- 2017-04-10 AU AU2017202344A patent/AU2017202344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ605871A (en) | 2015-02-27 |
| EP2585105A2 (en) | 2013-05-01 |
| US20110318327A1 (en) | 2011-12-29 |
| AU2011270672A1 (en) | 2013-02-14 |
| ES2643015T3 (es) | 2017-11-21 |
| JP2013542913A (ja) | 2013-11-28 |
| EP2585105A4 (en) | 2014-07-09 |
| CA2805449A1 (en) | 2011-12-29 |
| AU2017202344A1 (en) | 2017-04-27 |
| WO2011163652A3 (en) | 2013-07-11 |
| MX2013000324A (es) | 2013-02-01 |
| JP6063380B2 (ja) | 2017-01-18 |
| EP2585105B1 (en) | 2017-08-09 |
| WO2011163652A2 (en) | 2011-12-29 |
| AU2011270672B2 (en) | 2017-01-12 |
| CN103269709A (zh) | 2013-08-28 |
| KR20130043166A (ko) | 2013-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ605871A (en) | Treatment of sanfilippo syndrome type b | |
| NZ702800A (en) | Methods and compositions for cns delivery of heparan n-sulfatase | |
| NZ702808A (en) | Methods and compositions for cns delivery of iduronate-2-sulfatase | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| WO2012062228A3 (es) | Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas. | |
| CO6700848A2 (es) | Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad | |
| IN2012DN06720A (cg-RX-API-DMAC10.html) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2015001122A (es) | Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| PH12012501895A1 (en) | Long-acting formulations of insulins | |
| NZ702799A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CY1118934T1 (el) | Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης | |
| MX356808B (es) | Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| PH12012502082A1 (en) | Combination of active loaded granules with additional actives | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE FILED DATE HAS BEEN CORRECTED TO 25/06/2011 Effective date: 20151221 |
|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |